Search research articles
Contact Us
Filters
Showing results (161-170 of 261) with videos related to
Page
of 27
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 4, 2020
Phase I and Biomarker Study of the Wnt Pathway Modulator DKN-01 in Combination with Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer
Lipika Goyal, Cynthia Sirard, Michael Schrag, et al.
The Oncologist
|
May 21, 2010
Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer
Dan G Duda, Christopher G Willett, Marek Ancukiewicz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 1, 2009
Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice
Walid S Kamoun, Carsten D Ley, Christian T Farrar, et al.
Biorxiv : the Preprint Server for Biology
|
November 14, 2023
Preventing NK cell activation in the damaged liver induced by cabozantinib/PD-1 blockade increases survival in hepatocellular carcinoma models
Satoru Morita, Hiroto Kikuchi, Grace Birch, et al.
Neuro-Oncology Advances
|
January 4, 2021
Vascular dysfunction promotes regional hypoxia after bevacizumab therapy in recurrent glioblastoma patients
Elizabeth R Gerstner, Kyrre E Emblem, Yi-Fen Yen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 4, 2013
A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer
Andrew X Zhu, Richard S Finn, Mary Mulcahy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 19, 2019
Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma
Scott R Plotkin, Dan G Duda, Alona Muzikansky, et al.
Cancer
|
February 14, 2017
A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma
Lipika Goyal, Hui Zheng, Matthew B Yurgelun, et al.
The Oncologist
|
July 30, 2010
A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancer
Christopher G Willett, Dan G Duda, Marek Ancukiewicz, et al.
Hepatology (Baltimore, Md.)
|
August 6, 2019
Dual Programmed Death Receptor-1 and Vascular Endothelial Growth Factor Receptor-2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma
Kohei Shigeta, Meenal Datta, Tai Hato, et al.
Page
of 27
Search research articles
Search
Showing results (161-170 of 261) with videos related to
Sort By:
Page
of 27
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 4, 2020
Phase I and Biomarker Study of the Wnt Pathway Modulator DKN-01 in Combination with Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer
Lipika Goyal, Cynthia Sirard, Michael Schrag, et al.
The Oncologist
|
May 21, 2010
Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer
Dan G Duda, Christopher G Willett, Marek Ancukiewicz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 1, 2009
Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice
Walid S Kamoun, Carsten D Ley, Christian T Farrar, et al.
Biorxiv : the Preprint Server for Biology
|
November 14, 2023
Preventing NK cell activation in the damaged liver induced by cabozantinib/PD-1 blockade increases survival in hepatocellular carcinoma models
Satoru Morita, Hiroto Kikuchi, Grace Birch, et al.
Neuro-Oncology Advances
|
January 4, 2021
Vascular dysfunction promotes regional hypoxia after bevacizumab therapy in recurrent glioblastoma patients
Elizabeth R Gerstner, Kyrre E Emblem, Yi-Fen Yen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 4, 2013
A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer
Andrew X Zhu, Richard S Finn, Mary Mulcahy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 19, 2019
Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma
Scott R Plotkin, Dan G Duda, Alona Muzikansky, et al.
Cancer
|
February 14, 2017
A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma
Lipika Goyal, Hui Zheng, Matthew B Yurgelun, et al.
The Oncologist
|
July 30, 2010
A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancer
Christopher G Willett, Dan G Duda, Marek Ancukiewicz, et al.
Hepatology (Baltimore, Md.)
|
August 6, 2019
Dual Programmed Death Receptor-1 and Vascular Endothelial Growth Factor Receptor-2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma
Kohei Shigeta, Meenal Datta, Tai Hato, et al.
Page
of 27